PHILADELPHIA, Jan. 30, 2026 (GLOBE NEWSWIRE) -- WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of Lifecore Biomedical, Inc. (NASDAQ: LFCR) as a securities fraud class action has now reached a settlement. The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company. Current Lifecore Biomedical, Inc. (NASDAQ: LFCR) who have held shares since before October 7, 2020, can seek corporate reforms, the return of fund ...

Group 1 - Laughing Water Capital reported a fourth-quarter return of approximately 6.8%, with full-year returns at around 3.9% net of fees and expenses, outperforming the SP500TR and R2000 indexes in the previous year [1] - The cumulative returns since inception for Laughing Water Capital are about 400%, compared to approximately 332% for the SP500TR and 175% for the R2000 [1] - The portfolio is positioned to deliver strong long-term results despite recent underperformance in the current year [1] Group 2 - Lifecore Biomedical, Inc. (NASDAQ:LFCR) is highlighted as a key stock, with a market capitalization of $303.477 million and a one-month return of 0.75%, while its shares gained 25% over the last 52 weeks [2] - Lifecore Biomedical appreciated approximately 10% over the year, with a focus on increasing capacity utilization, which is crucial for earnings power improvement [3] - The company expects to fill its capacity with projected new business of approximately $11 million in the mid-term and $34 million in the long-term, representing about 11% of total capacity [3]

Performance Overview - Laughing Water Capital ("LWC") achieved a return of approximately 6.8% in Q4, resulting in a full-year return of about 3.9% after fees and expenses, compared to the SP500TR and R2000 which returned approximately 2.7% and 2.2% respectively in the same quarter [3] - Since inception, LWC's cumulative return is approximately 400%, outperforming the SP500TR's ~332% and the R2000's ~175% [4] Investment Philosophy - The company emphasizes investing in off-the-beaten-path businesses led by capable management, particularly during periods of uncertainty, believing this approach can yield outsized returns over time [6][8] - Despite the current market enthusiasm for sectors like artificial intelligence and technology, the company remains focused on fundamental business performance rather than market trends [7][8] Market Dynamics - Recent market trends have favored larger, growth-oriented companies, with a significant outperformance of large-cap stocks over small-cap stocks [10][15] - The SP500 has outperformed the equal-weight SP500 by 34% over the past three years, indicating a strong preference for larger companies [15] Specific Investments - Lifecore Biomedical is highlighted as a key investment, with expectations of significant growth due to its competitive advantages and increasing capacity utilization [13][14] - Liquidia Corp has seen early sales success with its drug Yutrephia, which has outperformed expectations, despite ongoing patent litigation with United Therapeutics [30][31] - NextNav Inc is positioned as a potential leader in providing a terrestrial backup to GPS, with bipartisan support for its proposal to repurpose spectrum for 5G use [36][39] Future Outlook - The company anticipates continued improvement in the fundamental performance of its investments, suggesting that over time, market recognition of these fundamentals will lead to better stock performance [62] - Management remains optimistic about the potential for significant upside in investments like Lifecore and Liquidia, while also acknowledging the challenges posed by market sentiment and timing [29][33]

Core Viewpoint - Grabar Law Office is investigating claims on behalf of shareholders of Lifecore Biomedical, Inc. regarding a securities fraud class action settlement, focusing on potential breaches of fiduciary duties by certain officers and directors [1][3]. Group 1: Settlement and Investigation - A federal securities class action against Lifecore Biomedical has reached a settlement, alleging that the company made materially false and misleading statements about its business and financial operations [3]. - The investigation is centered on whether Lifecore maintained adequate internal controls over financial reporting, which led to inaccurate financial statements that required restatement [3]. - The settlement allows shareholders who held shares before October 7, 2020, to seek corporate reforms and the return of funds to the company at no cost [2][4]. Group 2: Allegations and Implications - The class action complaint claims that Lifecore's remediation efforts regarding financial reporting deficiencies were ineffective, impairing its ability to file timely reports with the SEC [3]. - The allegations suggest that Lifecore's financial position and prospects were materially overstated, leading to misleading public statements throughout the relevant period [3].

It is easy to look at a chart that has run up ~25% YTD and assume the opportunity has passed. In many cases you would be right, but Lifecore Biomedical ( LFCR ) is currently exitingI'm a fundamental investor who targets situations where the market has pushed a company’s valuation far out of line with its underlying economics. My professional background in corporate financial analysis has deeply shaped my investment perspective, leading me to focus intensely on cash flow durability, balance sheet strength, a ...

Core Viewpoint - Grabar Law Office is investigating claims on behalf of shareholders of Lifecore Biomedical, Inc. regarding potential breaches of fiduciary duties by certain officers and directors [1] Group 1: Investigation and Claims - Lifecore Biomedical, Inc. shareholders who held shares before October 7, 2020, can seek corporate reforms, return of funds, and a court-approved incentive award at no cost [2] - A federal securities class action against Lifecore Biomedical and certain officers has reached a settlement, alleging that the defendants made materially false and misleading statements about the company's business and operations [3] Group 2: Allegations and Settlement - The class action complaint alleges that Lifecore maintained deficient internal controls over financial reporting, leading to inaccurate financial statements that required restatement [3] - The company and individual defendants entered into an agreement in principle to settle the class action in November 2025 [4]

Market Overview - U.S. stock index futures showed little change ahead of a low-volume trading session post-Christmas holiday [2] - Precious metals such as silver, gold, and platinum reached new all-time highs, continuing their significant upward trend this year [2] Economic Data Releases - Key economic data releases to monitor in the final week of the year include: - Crude oil inventories data on Monday - FOMC meeting minutes on Tuesday - Initial jobless claims and Chicago PMI for December on Wednesday - S&P Global Manufacturing PMI for December on Friday [3] Earnings Reports - Upcoming earnings reports for next week include: - Wednesday: Coffee Holding (JVA), 1933 Industries (TGIFF) - Thursday: Park Aerospace (PKE), Lifecore Biomedical (LFCR) - Friday: Taylor Devices (TAYD), Hurco (HURC) [4] Volatility Watch - Energy Fuels (UUUU) and Applied Digital (APLD) are expected to experience a volatile trading week based on options volume - The most overbought stocks include Hycroft Mining Holding (HYMC), Amicus (FOLD), and Charlotte's Web (CWBHF) - The most oversold stocks include CVR Energy (CVI), Tile Shop (TTSH), and Lamb Weston (LW) [5]

Core Viewpoint - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by certain officers and directors of Lifecore Biomedical, Inc. [1] Group 1: Legal Actions and Shareholder Rights - Long-term shareholders of Lifecore may seek corporate governance reforms, return of funds, court-approved financial incentives, or other benefits [2] - Shareholder involvement is crucial for improving company policies and enhancing shareholder value [3] Group 2: Firm's Background and Services - Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, recovering millions for defrauded investors [4]

Group 1 - Lifecore Biomedical, Inc. is set to be added to the Nasdaq Biotech Index effective December 22, 2025, as part of the annual reconstitution of the Nasdaq indexes [1] - The Nasdaq Biotechnology Index tracks the performance of Nasdaq-listed securities classified as biotechnology or pharmaceutical, calculated under a modified capitalization-weighted methodology [2] - Companies must meet specific eligibility requirements, including minimum market capitalization and average daily trading volume, to be included in the Nasdaq Biotechnology Index [2] Group 2 - Lifecore Biomedical is a fully integrated contract development and manufacturing organization (CDMO) specializing in the development, fill, and finish of sterile injectable pharmaceutical products [3] - The company has over 40 years of expertise in manufacturing premium, injectable-grade hyaluronic acid and partners with global and emerging biopharmaceutical and biotechnology companies [3]

Agreement Calls for Development Services and Tech Transfer in Preparation for Commercial Manufacturing of Injectable Pharmaceutical Product Partner’s Program Size Positions it to Become a Top Five Commercial Customer for Lifecore CHASKA, Minn., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has signed a CDMO master services agreement with a new large global pharm ...